Monte Rosa's MRT-8102 Reduces Heart Disease Risk by 85%

Monte Rosa Therapeutics (GLUE) announces positive Phase 1 results for MRT-8102, showing 85% reduction in inflammation markers and potential for preventing cardiovascular disease.